- Case report
- Open Access
- Open Peer Review
Multicentric Castleman’s disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report
© Rao et al.; licensee BioMed Central. 2015
- Received: 12 September 2014
- Accepted: 21 January 2015
- Published: 4 February 2015
Castleman’s disease is a rare lymphoproliferative disorder which occurs in localized and multicentric forms and can mimic lymphoma. Despite its well-known association with certain autoimmune diseases, including paraneoplastic pemphigus and myasthenia gravis, Castleman’s disease has not previously been associated with limbic encephalitis.
We report the case of a 47-year old Caucasian man who presented with subacute onset of constitutional symptoms, diffuse lymphadenopathy, and stereotyped spells involving olfactory aura, nausea, disorientation, and unresponsiveness. He was found to have focal dyscognitive seizures of temporal lobe origin, cerebrospinal fluid with lymphocytic pleocytosis, hyponatremia, and serum positive for voltage-gated potassium channel antibodies, consistent with limbic encephalitis. An extensive infectious workup was unrevealing, but lymph node biopsy revealed multicentric Castleman’s disease. His symptoms improved with antiepileptic drugs and immunotherapy.
This case highlights the clinical diversity of voltage-gated potassium channel autoimmunity and expands the association of Castleman’s disease and autoimmune syndromes to include limbic encephalitis. Clinicians should be aware that paraneoplastic disorders of the central nervous system can be related to underlying hematologic disorders such as Castleman’s disease.
- Castleman’s disease
- Limbic encephalitis
- Voltage-gated potassium channel
Castleman’s disease (CD) is a rare lymphoproliferative disorder characterized by enlarged, hyperplastic lymph nodes that can mimic lymphoma. First described in 1954 , CD occurs in several histologic variants, including hyaline-vascular, plasma cell, and mixed types. Two clinical presentations can be distinguished: a localized or unicentric form, which is typically indolent and treated with local excision, and a systemic or multicentric form (MCD), which usually involves the plasma cell variant and portends a worse prognosis. MCD presents with diffuse lymphadenopathy, hepatosplenomegaly, fevers, night sweats, and fatigue. The pathogenesis of MCD is thought to be driven by human herpesvirus 8 (HHV8), which latently infects B cells in healthy individuals but can reactivate in the setting of immune system compromise, such as human immunodeficiency virus (HIV) infection. Reactivated HHV8 promotes production of interleukin-6 (IL-6), which stimulates B cell proliferation and lymphoid hyperplasia, and treatment of MCD can be directed at lowering levels of this cytokine .
CD most commonly presents with lymphadenopathy in the neck, chest, and/or abdomen. Central nervous system (CNS) involvement is rare, but intracranial, extra-axial lesions mimicking meningiomas have been reported in CD and can present with seizures [3,4], presumably due to their direct impingement on cortex. CD has been associated with several autoimmune diseases , including paraneoplastic pemphigus, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, but only a single report describes a paraneoplastic CNS syndrome in the setting of CD . Limbic encephalitis (LE), a classic CNS autoimmune disorder, presents with cognitive changes and focal seizures of mesial temporal lobe origin. LE can occur with or without identifiable underlying malignancy and can be seronegative or associated with specific antibodies. Malignant hemopathies—including leukemia  and, more commonly, lymphomas —have been associated with paraneoplastic LE, but, to our knowledge, CD has not.
Here we report the case of a patient who presented with subacute onset of constitutional symptoms and seizures and was found to have MCD, LE, and voltage-gated potassium channel (VGKC) antibodies. This case illustrates novel linkage of two rare clinical entities through an antibody well-known to mediate paraneoplastic neurological syndromes.
While this workup was in progress, the patient described progressive memory difficulty and recurrent, stereotyped spells involving perception of an unpleasant odor followed by nausea and dizziness. The spells lasted about one minute, occurred up to seven times per day, and coincided with episodic confusion noticed by his girlfriend. A routine electroencephalogram (EEG) was normal, and the patient was treated empirically with levetiracetam without benefit.
The constellation of subacute encephalopathy, temporal lobe seizures, and mild lymphocytic CSF pleocytosis raised the possibility of autoimmune encephalitis. Serological analysis revealed elevated voltage-gated potassium channel (VGKC) antibodies (850 pmol/L; Athena Diagnostics, reference range 31–88 pmol/L). Testing for N-methyl-D-aspartate receptor and glutamic acid decarboxylase antibodies was negative. VGKC antibodies can be associated with underlying neoplastic disease, and, to further evaluate this possibility, excisional biopsy of a level V lymph node in the right neck was performed.
The patient was treated with two four-week cycles of weekly rituximab infusions followed by maintenance rituximab infusions every two months for a planned two-year course. Antiepileptic drug therapy with divalproex was continued with some dose adjustment required for breakthrough seizures. Serum IL-6 levels were not monitored to track response to therapy, but serial PET scans have shown decreased size and FDG-avidity of diffuse lymphadenopathy without complete resolution. A repeat VGKC antibody titer six months after initiation of rituximab was lower but remained elevated at 656 pmol/L. At last follow-up, the patient’s cough was persistent, now being managed with prednisone, but the constitutional symptoms that led to initial presentation had resolved.
This case illustrates the typical features of MCD: onset in middle age, non-specific constitutional symptoms suggestive of inflammatory disease, diffuse lymphadenopathy and hepatosplenomegaly mimicking lymphoma, and, often, cough or dyspnea, which is more common in HIV-positive patients and may relate to a non-infectious pulmonary interstitial lymphocytic infiltrate. Mild sensory polyneuropathy, as found in our patient, can occur in 20% of patients with MCD . Manifestations of MCD are thus non-specific and diagnosis is made by histopathology, which most commonly reveals the plasma cell variant. Although HHV8 is central to the pathogenesis of HIV-positive CD, its role in HIV-negative disease remains controversial  because HHV8 is found in only 50% of these patients . Our patient was found to be HIV-negative and HHV8-negative, which may represent a nosologically-distinct disease entity, termed idiopathic MCD, whose pathogenesis is speculated to involve autoimmune mechanisms . Thus, this case raises the intriguing possibility that VGKC antibodies might be important for the pathogenesis of certain forms of MCD.
Our patient also developed cardinal features of LE associated with VGKC antibodies, including subacute encephalopathy, temporal lobe seizures, CSF lymphocytic pleocytosis, and hyponatremia . Brain MRI was normal, as is the case in up to 45% of patients with LE and VGKC antibodies . VGKC antibodies are thought to be pathogenic in LE, but the antibodies are actually directed against epitopes in the extracellular domains of proteins tightly complexed with VGKCs in vivo; the most common target in LE is the leucine-rich glioma-inactivated 1 (LGI-1) protein . Although we did not test specifically for this immunoreactivity, our patient did not demonstrate the faciobrachial dystonic seizure semiology that often precedes onset of LE in LGI-1 antibody-positive patients .
Previous reports have described patients with intracranial CD lesions presenting with seizures [3,4], presumably due to mass effect and irritation of adjacent cortex. CD is also known to be associated with paraneoplastic syndromes affecting the peripheral nervous system (PNS), including myasthenia gravis and POEMS syndrome . One reported case of cerebellar degeneration in the setting of CD may represent an autoimmune CNS syndrome, but no antibody was identified . Only 30% of patients with antibodies against VGKC have tumors, but VGKC antibodies have been reported in association with thymoma and lung cancer . To our knowledge, this is the first report of CD associated with either LE or VGKC antibodies.
LE associated with VGKC antibodies is frequently responsive to immunotherapy, and reduction in antibody titer correlates with clinical improvement . Our patient’s seizures were relatively easily controlled with antiepileptic drug monotherapy, though we cannot exclude the possibility that steroids used later for pulmonary indications also contributed to seizure control. Rituximab was initiated primarily for treatment of MCD. That only modest decrease in VGKC antibody titer was seen following treatment with rituximab, however, may indicate that paraneoplastic LE in the setting of MCD is more treatment-resistant than other forms of LE. Three-year disease-free survival in HIV-negative patients with plasma cell variant MCD is 45% , so our patient’s prognosis remains guarded. Other treatment options, including the anti-IL-6 monoclonal antibody, siltuximab , are being considered.
The range of autoimmune disorders associated with CD is broader than previously known, and VGKC antibodies may play an important pathogenic role. In addition to paraneoplastic syndromes affecting the PNS, clinicians should be aware that CD can be associated with LE and other CNS manifestations even in the absence of overt intracranial disease.
Castleman’s disease can be associated with voltage-gated potassium channel antibodies and paraneoplastic syndromes involving the central nervous system. Although rare, Castleman’s disease should be considered in patients presenting with features of limbic encephalitis and evidence of an underlying lymphoproliferative disorder.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors thank Dr. Charlotte Jacobs for helpful discussions and expert oncological management of this patient.
- Castleman B, Towne VW. Case records of the Massachusetts general hospital: case No. 40231. N Engl J Med. 1954;250(23):1001–5.View ArticlePubMedGoogle Scholar
- van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind. Placebo-Controlled Trial Lancet Oncol. 2014;15(9):966–74.View ArticlePubMedGoogle Scholar
- Sotrel A, Castellano-Sanchez AA, Prusmack C, Birchansky S, Brathwaite C, Ragheb J. Castleman's disease in a child presenting with a partly mineralized solitary meningeal mass. Pediatr Neurosurg. 2003;38(5):232–7.View ArticlePubMedGoogle Scholar
- Matsumura K, Nakasu S, Tanaka T, Nioka H, Matsuda M. Intracranial localized Castleman's disease. Case report. Neurol Med Chir (Tokyo). 2005;45(1):59–65.View ArticleGoogle Scholar
- Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol. 2012;24(1):76–83.View ArticlePubMedGoogle Scholar
- Lee S, Le S. Paraneoplastic cerebellar degeneration with castleman disease: a case report. Neurology. 2014;82:P1.027.View ArticleGoogle Scholar
- Alcantara M, Bennani O, Verdure P, Lepretre S, Tilly H, Jardin F. Voltage-gated potassium channel antibody paraneoplastic limbic encephalitis associated with acute myeloid leukemia. Case Rep Oncol. 2013;6(2):289–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Graus F, Arino H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and Non-Hodgkin lymphomas. Blood. 2014;123(21):3230–8.View ArticlePubMedPubMed CentralGoogle Scholar
- van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8(7):486–98.PubMedGoogle Scholar
- Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of castleman disease. Cancer Control. 2014;21(4):266–78.PubMedGoogle Scholar
- Fajgenbaum DC, van Rhee F, Nabel CS. Hhv-8-negative, idiopathic multicentric castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924–33.View ArticlePubMedGoogle Scholar
- Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-Surface Central Nervous System Autoantibodies: Clinical Relevance and Emerging Paradigms. Ann Neurol. 2014;76(2):168–84.View ArticlePubMedPubMed CentralGoogle Scholar
- Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the Cns: New developments and future challenges. Lancet Neurol. 2011;10(8):759–72.View ArticlePubMedGoogle Scholar
- Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900.View ArticlePubMedGoogle Scholar
- Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology. 2008;70(20):1883–90.View ArticlePubMedGoogle Scholar
- Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(Pt 3):701–12.PubMedGoogle Scholar
- Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316–24.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.